Structure-Activity Relationship Study of CYM51010, an agonist for the µ-δ Opioid Receptor Heterodimer.

IF 1.5 4区 医学 Q4 CHEMISTRY, MEDICINAL
Ayaka Watanabe, Shuma Yamada, Haruka Yoshida, Miku Inagaki, Nao Atsumi, Aoba Matsushima, Naoki Takahashi, Naoto Ishibashi, Takumi Ogino, Ryoto Someya, Ai Taguchi, Ryo Kagaya, Karin Ashizawa, Hinako Mendori, Yusuke Karasawa, Kaori Ohshima, Akinobu Yokoyama, Miki Nonaka, Kanako Miyano, Fumika Karaki, Shigeto Hirayama, Kennosuke Itoh, Yasuhito Uezono, Hideaki Fujii
{"title":"Structure-Activity Relationship Study of CYM51010, an agonist for the µ-δ Opioid Receptor Heterodimer.","authors":"Ayaka Watanabe, Shuma Yamada, Haruka Yoshida, Miku Inagaki, Nao Atsumi, Aoba Matsushima, Naoki Takahashi, Naoto Ishibashi, Takumi Ogino, Ryoto Someya, Ai Taguchi, Ryo Kagaya, Karin Ashizawa, Hinako Mendori, Yusuke Karasawa, Kaori Ohshima, Akinobu Yokoyama, Miki Nonaka, Kanako Miyano, Fumika Karaki, Shigeto Hirayama, Kennosuke Itoh, Yasuhito Uezono, Hideaki Fujii","doi":"10.1248/cpb.c24-00188","DOIUrl":null,"url":null,"abstract":"<p><p>Although opioid analgesics are indispensable in treating pain, these drugs are accompanied by life-threatening side effects. While clinically relevant opioid drugs target the µ opioid receptor (MOR), a heterodimer between the MOR and the δ opioid receptor (DOR) has emerged as another target to develop safer analgesics. Although some heterodimer-preferring agonists have been reported so far, it is still difficult to activate the MOR/DOR heterodimer selectively in the presence of MOR or DOR monomers/homodimers. To gain insights to develop selective agonists for MOR/DOR, herein we prepared analogs of CYM51010, one of the reported heterodimer-preferring agonists, and collected structure-activity relationship information. We found that the ethoxycarbonyl group was needed for the activity for the heterodimer, although this group could be substituted with functional groups with similar sizes, such as an ethoxycarbonyl group. As for the acetylaminophenyl group, not a type of substituent, but rather a substituent located at a specific position (para-position) was essential for the activity. Changing the linker length between the acetylaminophenyl group and the piperidine moiety also had deleterious effects on the activity. On the other hand, the substitution of the acetylamino group with a trifluoroacetylamino group and the substitution of the phenethyl group with a benzyl group diminished the activities for the monomers/homodimers while keeping the activity for MOR/DOR, which enhanced the selectivity. Our findings herein will play an important role in developing selective agonists for MOR/DOR and for elucidating the physiological roles of this heterodimer in analgesic processes and in the establishment of side effects.</p>","PeriodicalId":9773,"journal":{"name":"Chemical & pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chemical & pharmaceutical bulletin","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1248/cpb.c24-00188","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Although opioid analgesics are indispensable in treating pain, these drugs are accompanied by life-threatening side effects. While clinically relevant opioid drugs target the µ opioid receptor (MOR), a heterodimer between the MOR and the δ opioid receptor (DOR) has emerged as another target to develop safer analgesics. Although some heterodimer-preferring agonists have been reported so far, it is still difficult to activate the MOR/DOR heterodimer selectively in the presence of MOR or DOR monomers/homodimers. To gain insights to develop selective agonists for MOR/DOR, herein we prepared analogs of CYM51010, one of the reported heterodimer-preferring agonists, and collected structure-activity relationship information. We found that the ethoxycarbonyl group was needed for the activity for the heterodimer, although this group could be substituted with functional groups with similar sizes, such as an ethoxycarbonyl group. As for the acetylaminophenyl group, not a type of substituent, but rather a substituent located at a specific position (para-position) was essential for the activity. Changing the linker length between the acetylaminophenyl group and the piperidine moiety also had deleterious effects on the activity. On the other hand, the substitution of the acetylamino group with a trifluoroacetylamino group and the substitution of the phenethyl group with a benzyl group diminished the activities for the monomers/homodimers while keeping the activity for MOR/DOR, which enhanced the selectivity. Our findings herein will play an important role in developing selective agonists for MOR/DOR and for elucidating the physiological roles of this heterodimer in analgesic processes and in the establishment of side effects.

μ-δ阿片受体异二聚体激动剂 CYM51010 的结构-活性关系研究
虽然阿片类镇痛药是治疗疼痛不可或缺的药物,但这些药物也伴随着危及生命的副作用。虽然临床上相关的阿片类药物以 µ 阿片受体(MOR)为靶点,但 MOR 和 δ 阿片受体(DOR)之间的异二聚体已成为开发更安全镇痛药的另一个靶点。虽然迄今已报道了一些异二聚体优先激动剂,但在存在 MOR 或 DOR 单体/同二聚体的情况下,仍难以选择性地激活 MOR/DOR 异二聚体。为了深入了解如何开发 MOR/DOR 的选择性激动剂,我们在本文中制备了 CYM51010 的类似物(已报道的异二聚体优先激动剂之一),并收集了结构-活性关系信息。我们发现,异二聚体的活性需要乙氧羰基,尽管该基团可以被类似大小的官能团(如乙氧羰基)取代。至于乙酰氨基苯基,其活性并非取决于取代基的类型,而是取决于位于特定位置(对位)的取代基。改变乙酰氨基苯基和哌啶之间的连接长度也会对活性产生不利影响。另一方面,用三氟乙酰氨基取代乙酰氨基和用苄基取代苯乙基会降低单体/同源二聚体的活性,而保持对 MOR/DOR 的活性,从而提高选择性。我们在本文中的发现将对开发 MOR/DOR 的选择性激动剂以及阐明这种异源二聚体在镇痛过程和副作用产生过程中的生理作用发挥重要作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.20
自引率
5.90%
发文量
132
审稿时长
1.7 months
期刊介绍: The CPB covers various chemical topics in the pharmaceutical and health sciences fields dealing with biologically active compounds, natural products, and medicines, while BPB deals with a wide range of biological topics in the pharmaceutical and health sciences fields including scientific research from basic to clinical studies. For details of their respective scopes, please refer to the submission topic categories below. Topics: Organic chemistry In silico science Inorganic chemistry Pharmacognosy Health statistics Forensic science Biochemistry Pharmacology Pharmaceutical care and science Medicinal chemistry Analytical chemistry Physical pharmacy Natural product chemistry Toxicology Environmental science Molecular and cellular biology Biopharmacy and pharmacokinetics Pharmaceutical education Chemical biology Physical chemistry Pharmaceutical engineering Epidemiology Hygiene Regulatory science Immunology and microbiology Clinical pharmacy Miscellaneous.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信